Skip to main content
Premium Trial:

Request an Annual Quote

Becton Dickinson's Q3 Revenues Rise 3 Percent on Bioscience Gains

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Becton Dickinson today reported 3 percent revenue growth for its third quarter ended June 30, led by double-digit revenue growth for its BD Biosciences business in the US. On a currency-neutral basis, its revenues grew around 9 percent.

The Franklin Lakes, NJ-based maker of medical devices, diagnostics, and life sciences research products brought in total revenues of $1.88 billion for the quarter, compared to $1.82 billion for the third quarter of 2009. The results beat analysts' consensus estimate for revenues of $1.85 billion.

BD's US sales increased 3 percent to $829.6 million from $805.4 million, and its international sales also increased around 3 percent to $1.05 billion from $1.01 billion.

Its BD Medical segment reported revenues of $992.8 million, up nearly 3 percent from $968.7 million for Q3 2009. Its BD Diagnostics segment had 2 percent revenue growth to $576.3 million from $566.4 million, and its BD Biosciences segment had 8 percent growth to $309.1 million from $285.2 million.

Within BD Biosciences, the firm's cell analysis products had around 20 percent revenue growth in the US to $84.4 million from $70.5 million year over year, while its Discovery Labware products sales were up 6 percent to $39.8 million from $37.6 million. Both of those businesses also increased revenues internationally but not as much as in the US, partially due to currency headwinds.

BD's net income for the quarter was $306.9 million, or $1.29 per share, down from $341 million, or $1.39 per share, for Q3 2009. Last year's third quarter included $20 million, or $.08 per share, tax benefit related to tax settlements in various jurisdictions, the firm said. Excluding that benefit, and on a foreign currency-neutral basis, BD's adjusted EPS for Q3 2010 was up 7 percent.

The firm also comfortably beat analysts' estimates for $1.24 per share.

"Despite the challenging global economy, we expect to deliver bottom-line growth of approximately 9 percent foreign-currency neutral, which is in line with our previously communicated range of 8 to 10 percent for the full fiscal year 2010," BD Chairman and CEO Edward Ludwig said in a statement.

BD spent $108.6 million on R&D during the quarter, a 10 percent increase from $98.5 million. Its SG&A spending declined around 2 percent to $423.7 million from $429.9 million.

BD said that it expects to report full-year 2010 revenue growth of approximately 5 percent, which is 1 percent lower than previously expected by the firm. It said the decrease is due to a weaker Euro and overall lower lab testing in the US.

BD also said that it is increasing its share repurchases up to $700 million from $550 million.

In early Thursday trade on the New York Stock Exchange, shares of BD were up 1 percent at $68.89.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.